CN1931369A - 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 - Google Patents
含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1931369A CN1931369A CNA2006100415310A CN200610041531A CN1931369A CN 1931369 A CN1931369 A CN 1931369A CN A2006100415310 A CNA2006100415310 A CN A2006100415310A CN 200610041531 A CN200610041531 A CN 200610041531A CN 1931369 A CN1931369 A CN 1931369A
- Authority
- CN
- China
- Prior art keywords
- docetaxel
- cyclodextrin
- beta
- schardinger dextrin
- sulphur butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 93
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims description 17
- 239000003814 drug Substances 0.000 title abstract description 26
- 229930012538 Paclitaxel Natural products 0.000 title abstract description 14
- 229960001592 paclitaxel Drugs 0.000 title abstract description 14
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract description 14
- 150000004291 polyenes Chemical class 0.000 title abstract 7
- 229940079593 drug Drugs 0.000 title description 10
- 230000008569 process Effects 0.000 title description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 98
- 238000002360 preparation method Methods 0.000 claims abstract description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000007787 solid Substances 0.000 claims abstract description 20
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 239000012982 microporous membrane Substances 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 135
- 229960003668 docetaxel Drugs 0.000 claims description 133
- 239000005864 Sulphur Substances 0.000 claims description 53
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 42
- YVDSCAPXSLVWCG-UHFFFAOYSA-N OCCC[S] Chemical compound OCCC[S] YVDSCAPXSLVWCG-UHFFFAOYSA-N 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 15
- 230000006837 decompression Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 8
- 230000001476 alcoholic effect Effects 0.000 claims description 7
- 239000000890 drug combination Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 229960004853 betadex Drugs 0.000 abstract description 4
- 239000001116 FEMA 4028 Substances 0.000 abstract description 3
- 231100001231 less toxic Toxicity 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 37
- 238000002347 injection Methods 0.000 description 17
- 229940090044 injection Drugs 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 12
- 229950005162 benexate Drugs 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 206010018910 Haemolysis Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000007928 solubilization Effects 0.000 description 4
- 238000005063 solubilization Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- -1 ester trihydrate Chemical class 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 241001116498 Taxus baccata Species 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- XIXYTCLDXQRHJO-RFVHGSKJSA-N Ramosetron hydrochloride Chemical compound Cl.C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 XIXYTCLDXQRHJO-RFVHGSKJSA-N 0.000 description 1
- 208000032827 Ring chromosome 9 syndrome Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940084491 cimetidine 300 mg Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
环糊精 | Ka | |
H2O | 60%EtOH | |
磺丁基-β-环糊精羟丙基-磺丁基-β-环糊精羟丙基-β-环糊精β-环糊精 | 205613051582379 | 6968301172694 |
包合物批号 | 环糊精* | 药物/环糊精比 | 乙醇残留量(%) |
2006011120060121200602212006030220060513200605112006040820060623 | ababbaa+bb | 1∶171∶171∶301∶301∶501∶501∶25∶251∶100 | 0.170.130.320.270.300.440.361.15 |
环糊精*(药物比) | 溶解度(mg/ml) | 增溶倍数 |
0a(1∶17)b(1∶17) | 0.00290315.00715.547 | 151695355 |
样品 | 含量(%) | |||
0天 | 光照 | 高温 | 高湿 | |
多烯紫杉醇原料包合物a包合物b | 99.67599.68499.645 | 90.17696.47897.985 | 87.85994.23595.407 | 83.87795.33195.310 |
稀释倍数 | 药物浓度mg/ml | 溶液状态* | ||||||||
0小时 | 5小时 | 10小时 | 15小时 | 20小时 | 2天 | 4天 | 6天 | 10天 | ||
11020501005001000 | 7.501.500.750.300.150.030.015 | +++++++ | +++++++ | +++++++ | +++++++ | +++++++ | -++++++ | -++++++ | -++++++ | -++++++ |
样品 | 含量(%) | ||||
0小时 | 5小时 | 10小时 | 24小时 | 96小时 | |
多烯紫杉醇原料包合物a包合物b | 99.67599.68499.645 | 99.02599.23999.554 | 97.38198.35999.002 | 93.43398.03597.459 | 86.38495.81296.386 |
Claims (4)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100415310A CN100411688C (zh) | 2006-09-12 | 2006-09-12 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
PCT/CN2006/002692 WO2008031285A1 (en) | 2006-09-12 | 2006-10-13 | Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process |
JP2009526995A JP5103476B2 (ja) | 2006-09-12 | 2006-10-13 | シクロデキストリン・ドセタキセルの包接体を含む薬物組成物及びその製造方法 |
EP06804920A EP2080524A4 (en) | 2006-09-12 | 2006-10-13 | PHARMACEUTICAL COMPOSITION CONTAINING DOCATEXEL-CYCLODEXTRIN INCLUSION COMPLEX AND METHOD OF MANUFACTURE |
US12/440,942 US8481511B2 (en) | 2006-09-12 | 2006-10-13 | Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process |
US13/932,434 US8765716B2 (en) | 2006-09-12 | 2013-07-01 | Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process |
US14/284,152 US20140336149A1 (en) | 2006-09-12 | 2014-05-21 | Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100415310A CN100411688C (zh) | 2006-09-12 | 2006-09-12 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1931369A true CN1931369A (zh) | 2007-03-21 |
CN100411688C CN100411688C (zh) | 2008-08-20 |
Family
ID=37877491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100415310A Active CN100411688C (zh) | 2006-09-12 | 2006-09-12 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (3) | US8481511B2 (zh) |
EP (1) | EP2080524A4 (zh) |
JP (1) | JP5103476B2 (zh) |
CN (1) | CN100411688C (zh) |
WO (1) | WO2008031285A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120065186A1 (en) * | 2008-11-15 | 2012-03-15 | Danping Li | Antimicrobial compositions |
CN103315978A (zh) * | 2013-07-12 | 2013-09-25 | 上海市第八人民医院 | 多西紫杉醇干酏剂及其制备方法和应用 |
CN108635592A (zh) * | 2018-05-16 | 2018-10-12 | 重庆理工大学 | 一种松萝酸-磺丁基-β-环糊精超分子复合物及其在制备口腔护理产品中的应用 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100486645C (zh) * | 2006-09-12 | 2009-05-13 | 南京师范大学 | 含有环糊精紫杉醇包合物的药物组合物及其制备方法 |
CN100411688C (zh) * | 2006-09-12 | 2008-08-20 | 南京师范大学 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
PL2934593T3 (pl) * | 2012-12-24 | 2020-05-18 | Softkemo Pharma Corp. | Kompozycja kabazytakselu |
PL3270912T3 (pl) * | 2015-03-16 | 2022-04-19 | Meridian Lab | Kompozycje farmaceutyczne zawierające kompleksy taksan-cyklodekstryna, sposób wytwarzania i sposoby zastosowania |
SI3411047T1 (sl) | 2016-02-04 | 2021-09-30 | Czap Research And Development, Llc | Sredstva za nadzorovano sproščeni in stratificirani kompleks vključitve ciklodekstrina |
WO2018109731A1 (en) * | 2016-12-16 | 2018-06-21 | Orbicular Pharmaceutical Technologies Private Limited | Pharmaceutical compositions of taxane and its derivatives |
AU2018263924B2 (en) * | 2017-05-03 | 2024-07-04 | Cydex Pharmaceuticals, Inc. | Composition containing cyclodextrin and busulfan |
CN113456586B (zh) * | 2018-07-25 | 2022-06-10 | 比卡生物科技(广州)有限公司 | 一种注射用多西他赛组合物及其制备方法 |
EP4142712A1 (en) * | 2020-04-30 | 2023-03-08 | Daxor Corp. | Fluorescent dye in ternary complex |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US5684169A (en) * | 1992-11-27 | 1997-11-04 | Ensuiko Sugar Refining Co., Ltd. | Cyclodextrin inclusion complex of taxol, and method for its production and its use |
JPH0753396A (ja) | 1993-08-19 | 1995-02-28 | Ensuiko Sugar Refining Co Ltd | タキソールのサイクロデキストリン包接物,その製造法および用途 |
JPH06157330A (ja) | 1992-11-27 | 1994-06-03 | Ensuiko Sugar Refining Co Ltd | タキソールのサイクロデキストリン包接物,その製造法と用途 |
HU213200B (en) * | 1993-05-12 | 1997-03-28 | Chinoin Gyogyszer Es Vegyeszet | The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production |
HUP9701945A3 (en) * | 1997-11-10 | 2000-04-28 | Hexal Ag | Pharmaceutical composition for injection containing cyclodextrin and taxoids |
CN1073384C (zh) | 1997-11-30 | 2001-10-24 | 周玉林 | 白瓜子开口机器 |
BR0116658A (pt) * | 2001-01-04 | 2003-12-30 | Daiichi Seiyaku Co | Preparação farmacêutica contendo ciclodextrina |
GB0127677D0 (en) * | 2001-11-19 | 2002-01-09 | Vianex S A | Inclusion complex |
KR20030041577A (ko) | 2001-11-20 | 2003-05-27 | 디디에스텍주식회사 | 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물 |
CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
CN100479807C (zh) * | 2002-08-15 | 2009-04-22 | 刘云清 | 药物输送系统——固体纳米药物的制备方法 |
CN1502332A (zh) * | 2002-11-25 | 2004-06-09 | 刘云清 | 抗癌药紫杉醇自乳化固体纳米粒——注射用紫杉醇的制备方法 |
CN1424112A (zh) | 2002-12-17 | 2003-06-18 | 上海医药工业研究院 | 难溶性药物的水溶性包合物及其制备方法 |
CN1182846C (zh) | 2003-03-14 | 2005-01-05 | 南开大学 | 水溶性抗癌药紫杉醇复合物及其制备方法 |
MEP34508A (en) * | 2003-03-28 | 2011-02-10 | Ares Trading Sa | Cladribine formulations for improved oral and transmucosal delivery |
CA2543443A1 (en) * | 2003-10-31 | 2005-05-12 | The University Of Kansas | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives |
CN100503647C (zh) * | 2005-11-02 | 2009-06-24 | 南京师范大学 | 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用 |
CN100486645C (zh) * | 2006-09-12 | 2009-05-13 | 南京师范大学 | 含有环糊精紫杉醇包合物的药物组合物及其制备方法 |
CN100411688C (zh) | 2006-09-12 | 2008-08-20 | 南京师范大学 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
-
2006
- 2006-09-12 CN CNB2006100415310A patent/CN100411688C/zh active Active
- 2006-10-13 JP JP2009526995A patent/JP5103476B2/ja not_active Expired - Fee Related
- 2006-10-13 US US12/440,942 patent/US8481511B2/en not_active Expired - Fee Related
- 2006-10-13 WO PCT/CN2006/002692 patent/WO2008031285A1/zh active Application Filing
- 2006-10-13 EP EP06804920A patent/EP2080524A4/en not_active Withdrawn
-
2013
- 2013-07-01 US US13/932,434 patent/US8765716B2/en active Active - Reinstated
-
2014
- 2014-05-21 US US14/284,152 patent/US20140336149A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120065186A1 (en) * | 2008-11-15 | 2012-03-15 | Danping Li | Antimicrobial compositions |
CN103315978A (zh) * | 2013-07-12 | 2013-09-25 | 上海市第八人民医院 | 多西紫杉醇干酏剂及其制备方法和应用 |
CN108635592A (zh) * | 2018-05-16 | 2018-10-12 | 重庆理工大学 | 一种松萝酸-磺丁基-β-环糊精超分子复合物及其在制备口腔护理产品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP5103476B2 (ja) | 2012-12-19 |
CN100411688C (zh) | 2008-08-20 |
EP2080524A4 (en) | 2011-07-20 |
US20100048685A1 (en) | 2010-02-25 |
US8481511B2 (en) | 2013-07-09 |
US8765716B2 (en) | 2014-07-01 |
US20130296268A1 (en) | 2013-11-07 |
US20140336149A1 (en) | 2014-11-13 |
WO2008031285A1 (en) | 2008-03-20 |
JP2010502653A (ja) | 2010-01-28 |
EP2080524A1 (en) | 2009-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100411688C (zh) | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 | |
CN1091368C (zh) | 含辅酶q10的药学组合物 | |
CN100486645C (zh) | 含有环糊精紫杉醇包合物的药物组合物及其制备方法 | |
CN106265510A (zh) | 一种肿瘤细胞内pH触发式释药的多级靶向聚合物胶束及其制备方法 | |
CN1486196A (zh) | 莫达非尼和环糊精的络合物 | |
CN106620717B (zh) | 一种具有逆转肿瘤多药耐药性功能的两亲性缀合物抗肿瘤纳米药及其制备方法和应用 | |
CN1748705A (zh) | 包含孕酮的新的可注射制剂 | |
CN1325685A (zh) | 可从乌墨蒲桃籽分离得到的混合物,它们的制备,及这些混合物及其某些组分作为药物的应用 | |
CN1760213A (zh) | 季铵化壳聚糖衍生物、其制备方法及含其的药物制剂 | |
CN1582159A (zh) | 增加了溶解度的黄烷醇木脂体制备物 | |
CN106924732A (zh) | 一种超声治疗用肿瘤靶向型血卟啉注射剂及其制备方法 | |
CN1448129A (zh) | 大蒜素和大蒜油环糊精衍生物包合物及其制备方法 | |
AU2007262496A1 (en) | Pharmaceutical composition for injectional, particularly targeted local administration | |
CN101084874A (zh) | 水溶性竹红菌素二氧化硅纳米粒的制备方法及其在制备静脉注射剂中的应用 | |
CN108685857A (zh) | 一种地佐辛纳米水性冻干粉针剂的制备方法及其应用 | |
CN100579512C (zh) | 水溶性竹红菌素二氧化钛纳米粒的制备方法 | |
CN112138001A (zh) | 一种槲皮素-低分子肝素-紫杉醇结合物、制备方法及应用 | |
CN113395958A (zh) | 基本上无10-溴-卡马西平的可注射卡马西平组合物 | |
CN105367563A (zh) | 利伐沙班晶iv型物质及制备方法和其组合物与用途 | |
CN1843346A (zh) | 含有紫杉醇类化合物的医药组合物及其制法 | |
CN1244574C (zh) | 水溶性黄豆苷元的制备方法及其应用 | |
SG et al. | PREPARATION AND IN-VITRO ASSESSMENT OF TOLBUTAMIDE LOADED NANOSPONGES | |
CN1224386C (zh) | 一种用于治疗癌症的夫马吉欣注射剂及其制备方法 | |
CN1559458A (zh) | 苏木提取物的新用途 | |
CN112190546A (zh) | 一种阿瑞匹坦制剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: NANJING JUHUAN MEDICAL TECHNOLOGY DEVELOPMENT CO., LTD. Owner name: HAINAN HEDETONG PHARMACEUTICAL TECHNOLOGY CO., LTD Free format text: FORMER OWNER: NANJING TEACHER-TRAINING UNIV. Effective date: 20100317 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210097 NO.122, NINGHAI ROAD, NANJING CITY, JIANGSU PROVINCE TO: 570125 ROOM 9003, HUAYIN BUILDING, NO.38, LONGKUN NORTH ROAD, HAIKOU CITY, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100317 Address after: Huayin North Longkun Road No. 38 building 570125 room 9003 Hainan city of Haikou Province Patentee after: HAINAN HEDETONG MEDICAL TECHNOLOGY Co.,Ltd. Address before: Nanjing City, Jiangsu province 210097 Ninghai Road No. 122 Co-patentee before: Nanjing Juhuan Medicine Technology Development Co.,Ltd. Patentee before: Nanjing Normal University |
|
ASS | Succession or assignment of patent right |
Owner name: HAINAN HUANGLONG PHARMACEUTICAL FACTORY CO., LTD. Free format text: FORMER OWNER: HAINAN HEDETONG PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20100603 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570125 ROOM 9003, HUAYIN BUILDING, NO.38, LONGKUN NORTH ROAD, HAIKOU CITY, HAINAN PROVINCE TO: 571127 GUILINYANG ECONOMIC DEVELOPMENT ZONE, HAIKOU CITY, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100603 Address after: 571127 Haikou Guilin Economic Development Zone, Hainan, China Patentee after: Hainan king long Pharmaceutical Factory Co.,Ltd. Address before: Huayin North Longkun Road No. 38 building 570125 room 9003 Hainan city of Haikou Province Patentee before: HAINAN HEDETONG MEDICAL TECHNOLOGY Co.,Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: HAINAN HUANGLONG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: HAINAN HUANGLONG PHARMACEUTICAL FACTORY CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 571127, Hainan Guilin Economic Development Zone, Haikou City, Hainan Province, Limited by Share Ltd pharmaceutical company Patentee after: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Address before: 571127 Haikou Guilin Economic Development Zone, Hainan, China Patentee before: Hainan king long Pharmaceutical Factory Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition containing cyclodextrin/polyene taxol and its prepn process Effective date of registration: 20150728 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Sanya branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2015460000003 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170328 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Sanya branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2015460000003 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition containing cyclodextrin/polyene taxol and its prepn process Effective date of registration: 20170427 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Sanya branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2017460000005 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170524 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Sanya branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2017460000005 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition containing cyclodextrin/polyene taxol and its prepn process Effective date of registration: 20170526 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Sanya branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2017460000008 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180720 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Sanya branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2017460000008 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition containing cyclodextrin/polyene taxol and its prepn process Effective date of registration: 20180920 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2018460000008 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20191031 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2018460000008 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition containing cyclodextrin / docetaxel inclusion complex and its preparation method Effective date of registration: 20200929 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980006541 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220419 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980006541 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition containing cyclodextrin / docetaxel inclusion complex and its preparation method Effective date of registration: 20220526 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980006463 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230726 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980006463 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Drug composition containing cyclodextrin/paclitaxel inclusion complex and its preparation method Effective date of registration: 20230804 Granted publication date: 20080820 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980051088 |